Chief Medicine Creation Officer News Today : Breaking News, Live Updates & Top Stories | Vimarsana

(1) Immunotherapy and Tyrosine Kinase Inhibitor Combination Approved for the Treatment of Patients With Advanced Endometrial Carcinoma That is Not Microsatellite Instability-High or Mismatch Repair Deficient, Who Have Disease Progression Following Prior Systemic Therapy in Any Setting and Are Not Candidates for Curative Surgery or Radiation Study Results Demonstrated Statistically Significant Improvements in Overall Survival, Progression-Free Survival and Overall Response Rate, Helping to Address a Significant Unmet Need in Advanced Endometrial Carcinoma TOKYO and KENILWORTH, N.J., July 23, 2021 - (JCN Newswire) - Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) today announced that the U.S. Food and Drug Administration (FDA) has approved the combination of LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus KEYTRUDA, the anti-PD-1 therapy from Merck & Co., Inc., Keni

United statesGregory lubinieckiVicky makkerOncology clinical researchDrug administrationOncology business group at eisaiEisai co ltdMerck co incResearch laboratoriesMemorial sloan kettering cancer centerTyrosine kinase inhibitor combination approvedPatients with advanced endometrial carcinoma thatNot microsatellite instability highMismatch repair deficientAny settingAre not candidates